{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-005458","form_type":"8-K","ticker":"CRVS","cik":"0001626971","company_name":"Corvus Pharmaceuticals, Inc.","filed_at":"2022-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.407001+00:00","generated_at":"2026-06-24T02:49:59.013145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Corvus prioritizes CPI-818; pauses mupadolimab Phase 2; Q2 net loss $8.4M","bullets":["Cash, cash equivalents and marketable securities $56.7M as of June 30, 2022, down from $69.5M at Dec 31, 2021.","Net loss $8.4M for Q2 2022 vs $11.8M for Q2 2021; R&D expenses fell to $4.9M from $9.1M.","CPI-818 200 mg cohort: 1 CR lasting 25 months, 1 nodal CR 16 months, 1 PR ongoing; no DLTs up to 600 mg.","Pausing start of randomized Phase 2 trial of mupadolimab in front-line NSCLC to focus on CPI-818 and conserve capital.","Expects cash runway into early 2024; full year 2022 net cash use $27-29M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-005458","json":"https://secwatch.observer/filing/0001171843-22-005458.json","markdown":"https://secwatch.observer/filing/0001171843-22-005458.md","text":"https://secwatch.observer/filing/0001171843-22-005458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1626971/000117184322005458/0001171843-22-005458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1626971/000117184322005458/f8k_080822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:49:59.013145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}